(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 March 2018 (22.03.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/052556 A8

(51) International Patent Classification:
C07K 16/00 (2006.01) *A61K 39/00* (2006.01)
C07K 16/10 (2006.01)

(21) International Application Number:
PCT/US2017/045126

(22) International Filing Date:
02 August 2017 (02.08.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/370,201 02 August 2016 (02.08.2016) US
62/485,671 14 April 2017 (14.04.2017) US

(71) Applicant: **VISTERRA, INC.** [US/US]; 275 2nd Avenue, 4th Floor, Waltham, Massachusetts 02451 (US).

(72) Inventors: **VISWANATHAN, Karthik**; 1 John Swift Road, Acton, MA 01720 (US). **RAMAKRISHNAN, Boopathy**; 605 Middle Street, Unit 19, Braintree, MA 02184 (US). **BOOTH, Brian**; 99 Cass Street, West Roxbury, MA 02132 (US). **NARAYAN, Kristin**; 150 Maple St., Lexington, MA 02420 (US). **WOLLACOTT, Andrew, M.**; 16 Woodchester Drive, Milton, MA 02186 (US).

(74) Agent: **COLLAZO, Diana, M.**; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: ENGINEERED POLYPEPTIDES AND USES THEREOF



FIG. 1

(57) Abstract: Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders. In particular, Fc regions comprising either one or multiple mutations selected from the partcicular mutations disclosed in Table 1 are disclosed. Certain of said mutations result in increased affinity for the neonatal Fc receptor (FcRn), and certain of said mutations result in elnaced half-life of engineered antibodies and also have an impact on effector functions. Particular disclosed mutations are M252Y, S254T, T256E, L309N, T250Q, M428L, N434S, N434A, T307A, E380A, N434A, M252Y, S254T, T256E, or a combination thereof as e.g. T256D/Q311V/A378V, H285N/ T307Q/N315D, H285D/T307Q/A378V, T307Q/Q311V/A378V, T256D/ N286D/T307R/Q311V/A378V, or T256D/T307R/Q311.

WO 2018/052556 A8

[Continued on next page]

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) **Date of publication of this corrected version:**
14 March 2019 (14.03.2019)

(15) **Information about Correction:**
see Notice of 14 March 2019 (14.03.2019)